安科生物：三季度公司实现营业收入、净利润的双增长

Core Insights - The company reported double growth in revenue and net profit for the third quarter, primarily driven by increased sales of growth hormones and antibody drugs [1] - In the fourth quarter, the company aims to enhance operational efficiency and effectiveness, further solidifying the stable growth of its main business while accelerating the improvement of other business segments to achieve the restorative growth target set at the beginning of the year [1] Revenue and Profit Growth - The third quarter saw a significant increase in both operating income and net profit, attributed to the growth in the main business areas of growth hormones and antibody drugs [1] - The company is focused on maintaining this growth trajectory and improving overall business performance in the upcoming quarter [1] Future Outlook - The company plans to continue enhancing operational efficiency and effectiveness in the fourth quarter [1] - There is a commitment to consolidating the stable growth of the main business while also working on the improvement of other business areas [1] - The goal is to achieve the restorative growth target established at the beginning of the year [1]